tradingkey.logo

Stereotaxis Inc

STXS
查看詳細走勢圖
2.445USD
+0.105+4.49%
收盤 12/22, 16:00美東報價延遲15分鐘
222.70M總市值
虧損本益比TTM

Stereotaxis Inc

2.445
+0.105+4.49%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.49%

5天

+5.39%

1月

+5.39%

6月

+19.85%

今年開始到現在

+7.24%

1年

+4.04%

查看詳細走勢圖

TradingKey Stereotaxis Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Stereotaxis Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名111/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價4.25。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Stereotaxis Inc評分

相關信息

行業排名
111 / 208
全市場排名
266 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
4.250
目標均價
+80.08%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Stereotaxis Inc亮點

亮點風險
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
業績增長期
公司處於發展階段,最新年度總收入26.92M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入26.92M美元
估值合理
公司最新PE估值-8.30,處於3年歷史合理位
機構減倉
最新機構持股41.68M股,環比減少8.77%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉5.27K股

Stereotaxis Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Stereotaxis Inc簡介

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
公司代碼STXS
公司Stereotaxis Inc
CEOFischel (David Leo)
網址https://www.stereotaxis.com/

常見問題

Stereotaxis Inc(STXS)的當前股價是多少?

Stereotaxis Inc(STXS)的當前股價是 2.445。

Stereotaxis Inc 的股票代碼是什麼?

Stereotaxis Inc的股票代碼是STXS。

Stereotaxis Inc股票的52週最高點是多少?

Stereotaxis Inc股票的52週最高點是3.590。

Stereotaxis Inc股票的52週最低點是多少?

Stereotaxis Inc股票的52週最低點是1.540。

Stereotaxis Inc的市值是多少?

Stereotaxis Inc的市值是222.70M。

Stereotaxis Inc的淨利潤是多少?

Stereotaxis Inc的淨利潤為-25.35M。

現在Stereotaxis Inc(STXS)的股票是買入、持有還是賣出?

根據分析師評級,Stereotaxis Inc(STXS)的總體評級為買入,目標價格為4.250。

Stereotaxis Inc(STXS)股票的每股收益(EPS TTM)是多少

Stereotaxis Inc(STXS)股票的每股收益(EPS TTM)是-0.282。
KeyAI